Bio-Rad Q1 GAAP net loss $527M ($19.55/share); net sales +1.1% to $592.1M

BIO-RAD LABORATORIES, INC.

2026-Q1 EPS reported -$19.55 revenue$592,100,000

Net sales $592.1M, up 1.1% YoY; GAAP gross margin 52.3% (flat YoY), non-GAAP gross margin 53.1%.
GAAP net loss $527.1M (diluted EPS -$19.55) vs prior-year net income $64.0M ($2.29).
Non-GAAP net income $50.9M ($1.89 diluted EPS); non-GAAP operating income $39.3M, down from $63.0M.
Operating cash flow $108.1M; free cash flow $78.1M; repurchased ~176k shares during Q1.
Management cited challenging academic markets and Middle East conflict as headwinds.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO-RAD LABORATORIES, INC. reported first quarter ended March 31, 2026 results: revenue $592.1 million, net income $(527.1) million, EPS $(19.55) per diluted share.

Period: first quarter ended March 31, 2026
Revenue: $592.1 million
Net income: $(527.1) million
EPS: $(19.55) per diluted share
Result: reported results

Exact text from the filing

Financial Results Highlights GAAP Results Q1 2026 Q1 2025 Net sales (millions) $ 592.1 $ 585.4 Gross margin 52.3 % 52.3 % Income from operations (millions) $ 34.1 $ 23.7 Net income (loss) (millions) $ (527.1) $ 64.0 Income (loss) per diluted share $ (19.55) $ 2.29

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-RAD LABORATORIES, INC. filing history →

Source: SEC EDGAR

accession 0000012208-26-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.